Catalent Announces Multi-Year Supply Agreement with Aurinia Pharmaceuticals

Through the agreement, Catalent will manufacture LUPKYNIS (voclosporin), Aurinia’s drug for the treatment of adult patients with lupus nephritis, at its pharmaceutical softgel center of excellence in St. Petersburg, FL.

Catalent announced on Feb. 18, 2021 that it has entered into a multi-year commercial supply agreement with Aurinia Pharmaceuticals, a Canadian pharmaceutical company, for LUPKYNIS (voclosporin), a drug for the treatment of adult patients with lupus nephritis, a complication that stems from the autoimmune disease systemic lupus erythematosus.

The drug, which was approved by FDA in January 2021, will be manufactured as a softgel dosage form at Catalent’s pharmaceutical softgel center of excellence in St. Petersburg, FL, Catalent said in a company press release.

“Catalent has a long track record in bringing novel drugs to market and has supported over 80% of all prescription pharmaceutical softgel brand launches in the U[nited] S[tates]. It has nearly 90 years of experience in the formulation and manufacturing of softgels for both pharmaceutical and consumer health products, which it has drawn upon to jointly develop LUPKYNIS with Aurinia,” said Dr. Aris Gennadios, president, Softgel and Oral Technologies, Catalent, in the press release. “We know the benefits that the dosage form offers developers and patients and look forward to working with Aurinia on the commercial production of this innovative therapeutic option for patients with lupus nephritis going forward, having previously partnered on its development.”

Source: Catalent